Biogen’s Qalsody (tofersen) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the first ...

Rezpegaldesleukin, which has already been granted FDA fast track designation for moderate-to-severe atopic dermatitis, is ...

Inclusion isn’t just about eligibility; it’s about participation Trials often demand time, travel and flexibility, resources ...

Eli Lilly’s Alzheimer’s disease (AD) drug donanemab has been recommended by the European Medicines Agency’s human medicines ...

Clinical trial patient recruitment and retention practices have significantly advanced over the last 15 years thanks to ...

Artificial intelligence (AI) in clinical research has the potential to accelerate patient access to new treatments by ...

Sanofi’s Sarclisa (isatuximab) has been approved by the European Commission (EC) to treat newly diagnosed multiple myeloma ...

Listening to patients and HCPs helps strike the right notes to deliver harmony across engagement and activation ...

AstraZeneca’s Imfinzi (durvalumab) has been granted priority review by the US Food and Drug Administration (FDA) to treat ...

Merck & Co – known as MSD outside of the US and Canada – has unveiled a new cost-cutting plan aimed at saving $3bn every year ...

So far this year, we have witnessed several announcements that could have a major impact on the clinical trials market and ...

Moderna’s LP.8.1-adapted COVID-19 vaccine has been recommended by the European Medicines Agency (EMA)’s human medicines ...